SS
ENGN icon

SBI Securities’s enGene Therapeutics ENGN Stock Holding History

SBI Securities’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48 Hold
28
– – ﹤0.01% 3680
2026
Q1 		$191 Hold
28
– – ﹤0.01% 3235
2025
Q4 		$253 Sell
28
-3
-10% -$24 ﹤0.01% 3137
2025
Q3 		$212 Buy
31
+1
+3% +$5 ﹤0.01% 3298
2025
Q2 		$109 Hold
30
– – ﹤0.01% 3512
2025
Q1 		$134 Hold
30
– – ﹤0.01% 3348
2024
Q4 		$200 Buy
+30
New +$233 ﹤0.01% 3240

Other funds holding ENGN

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
FA
Fountainhead AM Warren, New Jersey $135M AUM 24.26% 1-Year Est. Return
PP
PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SBI Securities's ENGN Position: Q2 2026 in Review

SBI Securities held its enGene Therapeutics (ENGN) position steady in Q2 2026 at 28 shares worth $48. The position accounts for ﹤0.01% of the portfolio, ranked #3680.

SBI Securities first reported a position in ENGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $253 in Q4 2025. 11 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • SBI Securities held 28 shares of enGene Therapeutics worth $48 as of Q2 2026.
  • SBI Securities left its enGene Therapeutics share count unchanged in Q2 2026.
  • enGene Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3680 holding.
  • SBI Securities first reported a position in enGene Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's enGene Therapeutics position peaked at $253 in Q4 2025.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.